PTC Therapeutics, Inc. (PTCT) Stock
Key stats
- Market cap
- $5.42B
- Price / Earnings ratio
- -50.6x
- EPS (TTM)
- -$1.46
- Volume
- Loading
- 52-week high
- $90.87
- 52-week low
- $58.80
Source: third-party data provider, as of November 13, 2026
Compare with PTCT
Recent news
PTC Therapeutics Q3 Earnings Call Highlights
PTC Therapeutics Q3 Earnings Call Highlights
PTCT
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
PTCT
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
PTCT
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
PTCTNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 52.04
- MACD 12/26/9
- 0.36
- EMA 9 of MACD
- -0.02
- MACD histogram
- 0.38
- SMA 50
- $64.44
- Price above SMA 50
- EMA 50
- $65.24
- Price below EMA 50
- SMA 200
- $70.29
- Price below SMA 200
- EMA 200
- $69.80
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.09 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
PTC Therapeutics Q3 Earnings Call Highlights
PTC Therapeutics Q3 Earnings Call Highlights
PTCTPTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
PTCTPTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
PTCTAnalysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
PTCT
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
PTCT
PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PTCT
PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
PTCT
PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates
PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates
PTCT
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
PTCT
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
PTCTNews tone: automated (AI) classification of the article's content, not a price prediction.
About PTC Therapeutics, Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | CEO & Director | 1972 |
| Mr. Pierre Gravier M.S. | Chief Financial Officer | 1985 |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder & Independent Director | 1946 |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 1967 |
| Mr. Eric Pauwels | Chief Business Officer | 1962 |
| Dr. Lee Scott Golden M.D., Ph.D. | Executive VP & Chief Medical Officer | 1968 |
| Ms. Christine Utter CPA | Senior VP, Chief Accounting Officer & Head of People Services | 1979 |
| Ms. Linda Montella Carter | Senior VP & Chief Information Officer | — |
| Ms. Ellen Cavaleri | Head of Investor Relations | — |
| Mr. Mark Elliott Boulding J.D. | Executive VP & Chief Legal Officer | 1961 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 52.04
- MACD 12/26/9
- 0.36
- EMA 9 of MACD
- -0.02
- MACD histogram
- 0.38
- SMA 50
- $64.44
- Price above SMA 50
- EMA 50
- $65.24
- Price below EMA 50
- SMA 200
- $70.29
- Price below SMA 200
- EMA 200
- $69.80
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $77.00
- Average
- $106.00
- High
- $137.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -4.3 | +10.9 | ||||||||||
| 2022 | -5.5 | -13.3 | +8.7 | -14.8 | -18.8 | +37.8 | +4.1 | +11.3 | -3.0 | -25.4 | +10.0 | -8.1 |
| 2023 | +20.3 | -7.8 | +7.1 | +16.3 | -23.9 | -6.5 | -2.6 | -2.9 | -44.1 | -11.7 | +24.8 | +14.9 |
| 2024 | -7.0 | +8.3 | -9.0 | +12.5 | +6.4 | -18.3 | +8.6 | +8.0 | +11.0 | +10.7 | +8.4 | -13.3 |
| 2025 | +0.0 | +10.5 | -3.6 | +7.0 | -2.0 | +0.0 | +7.2 | -5.4 | +17.1 | +10.2 | +26.6 | -4.1 |
| 2026 | -1.6 | -8.9 | +2.7 | -5.4 | +13.4 | +10.5 | -16.4 | +2.1 | -8.2 | -6.5 | +6.6 |
